Heart 1998;79:331-336 ( April )

Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population

F Cecchi,^a I Olivotto,^a A Montereggi,^a G Squillatini,^a A Dolara,^a B J Maron^b

^a Cardiologia di S Luca, Ospedale di Careggi, Florence, Italy, ^b Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA

Correspondence to: Dr F Cecchi, Via Jacopo Nardi, 30 Firenze, 50132, Italy.

Accepted for publication 29 September 1997

BackgroundAmiodarone has been reported to reduce the likelihood of sudden death in patients with hypertrophic cardiomyopathy (HCM). However, data regarding the clinical course in HCM have traditionally come from selected referral populations biased toward assessment of high risk patients.
AimsTo evaluate antiarrhythmic treatment for sudden death in an HCM population not subject to tertiary referral bias, closely resembling the true disease state present in the community.
MethodsCardiovascular mortality was assessed in relation to the occurrence of non-sustained ventricular tachycardia (NSVT) on 24 or 48 hour ambulatory Holter recording, a finding previously regarded as a marker for sudden death, particularly when the arrhythmia was frequent, repetitive or prolonged. 167 consecutive patients were analysed by multiple Holter ECG recordings (mean (SD) 157 (129) hours) and followed for a mean of 10 (5) years. Only patients with multiple repetitive NSVT were treated with amiodarone, and in relatively low doses (220 (44) mg/day).
ResultsNine HCM related deaths occurred: 8 were the consequence of congestive heart failure, but only 1 was sudden and unexpected. Three groups of patients were segregated based on their NSVT profile: group 1 (n = 39), multiple ( 2 runs) and repetitive bursts (on  2 Holters) of NSVT, or prolonged runs of ventricular tachycardia, included 4 deaths due to heart failure; group 2 (n = 38), isolated infrequent bursts of NSVT, included 1 sudden death; group 3 (n = 90), without NSVT, included 4 heart failure deaths. Kaplan-Meier survival analysis showed no significant differences in survival between the three groups throughout follow up.
ConclusionsIn an unselected patient population with HCM, isolated, non-repetitive bursts of NSVT were not associated with adverse prognosis and so this arrhythmia does not appear to justify chronic antiarrhythmic treatment. Amiodarone, administered in relatively low doses, did not carry an independent and additive risk for cardiac mortality. Amiodarone may have contributed to the absence of sudden cardiac death in patients believed to be at higher risk because of multiple repetitive NSVT.

Keywords: hypertrophic cardiomyopathy;  ventricular tachycardia;  amiodarone

---

© 1998 by Heart
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Ostman-Smith, I., Wisten, A., Nylander, E., Bratt, E.-L., de-Wahl Granelli, A., Oulhaj, A., Ljungstrom, E. (2009). Electrocardiographic amplitudes: a new risk factor for sudden death in hypertrophic cardiomyopathy. Eur Heart J 0: ehp443v1-ehp443 [Abstract] [Full Text]  
• Haghjoo, M., Mohammadzadeh, S., Taherpour, M., Faghfurian, B., Fazelifar, A. F., Alizadeh, A., Rad, M. A., Sadr-Ameli, M. A. (2009). ST-segment depression as a risk factor in hypertrophic cardiomyopathy. Europace 11: 643-649 [Abstract] [Full Text]  
• Soor, G S, Luk, A, Ahn, E, Abraham, J R, Woo, A, Ralph-Edwards, A, Butany, J (2009). Hypertrophic cardiomyopathy: current understanding and treatment objectives. J. Clin. Pathol. 62: 226-235 [Abstract] [Full Text]  
• Vassallo, P., Trohman, R. G. (2007). Prescribing Amiodarone: An Evidence-Based Review of Clinical Indications. JAMA 298: 1312-1322 [Abstract] [Full Text]  
• Melacini, P, Maron, B J, Bobbo, F, Basso, C, Tokajuk, B, Zucchetto, M, Thiene, G, Iliceto, S (2007). Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart 93: 708-710 [Abstract] [Full Text]  
• Enseleit, F., Duru, F. (2006). Long-term continuous external electrocardiographic recording: a review.. Europace 8: 255-266 [Abstract] [Full Text]  
• Adabag, A. S., Casey, S. A., Kuskowski, M. A., Zenovich, A. G., Maron, B. J. (2005). Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol 45: 697-704 [Abstract] [Full Text]  
• Frenneaux, M. P (2004). Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy. Heart 90: 570-575 [Full Text]  
• (2004). A patient with recurrent syncope. Postgrad. Med. J. 80: 120-121 [Full Text]  
• Maron, B. J., McKenna, W. J., Danielson, G. K., Kappenberger, L. J., Kuhn, H. J., Seidman, C. E., Shah, P. M., Spencer, W. H. III, Spirito, P., Ten Cate, F. J., Wigle, E. D., Vogel, R. A., Abrams, J., Bates, E. R., Brodie, B. R., Danias, P. G., Gregoratos, G., Hlatky, M. A., Hochman, J. S., Kaul, S., Lichtenberg, R. C., Lindner, J. R., O'rourke, R. A., Pohost, G. M., Schofield, R. S., Tracy, C. M., Winters, W. L. Jr, Klein, W. W., Priori, S. G., Alonso-Garcia, A., Blomstrom-Lundqvist, C., De Backer, G., Deckers, J., Flather, M., Hradec, J., Oto, A., Parkhomenko, A., Silber, S., Torbicki, A. (2003). American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42: 1687-1713 [Full Text]  
• Writing Committee Members, , Maron, B. J., McKenna, W. J., Danielson, G. K., Kappenberger, L. J., Kuhn, H. J., Seidman, C. E., Shah, P. M., Spencer, W. H. III, Spirito, P., Ten Cate, F. J., Wigle, E. D., ACCF Task Force on Clinical Expert Consensus Docum, , Vogel, R. A., Abrams, J., Bates, E. R., Brodie, B. R., Danias, P. G., Gregoratos, G., Hlatky, M. A., Hochman, J. S., Kaul, S., Lichtenberg, R. C., Lindner, J. R., O'Rourke, R. A., Pohost, G. M., Schofield, R. S., Tracy, C. M., Winters, W. L. Jr, ESC Committee for Practice Guidelines Members, , Klein, W. W., Priori, S. G., Alonso-Garcia, A., Blomstrom-Lundqvist, C., De Backer, G., Deckers, J., Flather, M., Hradec, J., Oto, A., Parkhomenko, A., Silber, S., Torbicki, A. (2003). American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 24: 1965-1991 [Full Text]  
• Monserrat, L., Elliott, P. M., Gimeno, J. R., Sharma, S., Penas-Lado, M., McKenna, W. J. (2003). Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 42: 873-879 [Abstract] [Full Text]  
• Olivotto, I., Gistri, R., Petrone, P., Pedemonte, E., Vargiu, D., Cecchi, F. (2003). Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 41: 315-321 [Abstract] [Full Text]  
• Maron, B. J. (2002). Hypertrophic Cardiomyopathy: A Systematic Review. JAMA 287: 1308-1320 [Abstract] [Full Text]  
• Janse, M.J., De Bakker, J.M.T. (2001). Arrhythmia substrate and management in hypertrophic cardiomyopathy: from molecules to implantable card ioverter-defibrillators. Eur Heart J Suppl 3: L15-L20 [Abstract]  
• Priori, S.G., Aliot, E., Blomstrom-Lundqvist, C., Bossaert, L., Breithardt, G., Brugada, P., Camm, A.J., Cappato, R., Cobbe, S.M., Di Mario, C., Maron, B.J., McKenna, W.J., Pedersen, A.K., Ravens, U., Schwartz, P.J., Trusz-Gluza, M., Vardas, P., Wellens, H.J.J., Zipes, D.P. (2001). Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 22: 1374-1450  
• Elliott, P. M., Poloniecki, J., Dickie, S., Sharma, S., Monserrat, L., Varnava, A., Mahon, N. G., McKenna, W. J. (2000). Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 36: 2212-2218 [Abstract] [Full Text]  
• Maron, B. J., Olivotto, I., Spirito, P., Casey, S. A., Bellone, P., Gohman, T. E., Graham, K. J., Burton, D. A., Cecchi, F. (2000). Epidemiology of Hypertrophic Cardiomyopathy-Related Death : Revisited in a Large Non-Referral-Based Patient Population. Circulation 102: 858-864 [Abstract] [Full Text]  
• Saumarez, R.C., Grace, A.A. (2000). Paced ventricular electrogram fractionation and sudden death in hypertrophic cardiomyopathy and other non-coronary heart diseases. Cardiovasc Res 47: 11-22 [Full Text]  
• Zimetbaum, P. J., Josephson, M. E. (1999). The Evolving Role of Ambulatory Arrhythmia Monitoring in General Clinical Practice. ANN INTERN MED 130: 848-856 [Abstract] [Full Text]  
• PRASAD, K, FRENNEAUX, M P (1998). Hypertrophic cardiomyopathy: is there a role for amiodarone?. Heart 79: 317-318 [Full Text]